Comparison
Octreotide vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Healing
CAS no.
83150-76-9
no data
Molecular weight
1019.24 g/mol
888 g/mol
Half-life
1.7 h
no data
Sequence
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Ac-LKKTETQMechanism of action
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
5
3
of which in humans
4
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
2
2